In a report released today, Alexander Galitsa from Hauck & Aufhaeuser downgraded STRATEC Biomedical (0RAR – Research Report) to a Sell, with a price target of €31.00. The company’s shares closed yesterday at €39.94.
According to TipRanks, Galitsa is ranked #4570 out of 9121 analysts.
Currently, the analyst consensus on STRATEC Biomedical is a Hold with an average price target of €43.00.
Based on STRATEC Biomedical’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of €66.97 million and a net profit of €4.5 million. In comparison, last year the company earned a revenue of €61.92 million and had a net profit of €3.61 million
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
STRATEC Biomedical (0RAR) Company Description:
Stratec SE designs and manufactures automated analyzer systems for laboratory data management and solutions for molecular diagnostic sample preparation and stabilization. Its business segments are Instrumentation, Diatron, Smart Consumables, and Others. The company generates maximum revenue from the Instrumentation segment. Its Instrumentation segment is engaged in designing and manufacturing automated analyzer systems for the clinical diagnostics and biotechnology customers. The Diatron segment comprises the business with systems, system components, consumables and tests in the low throughput hematology and clinical chemistry segment. Its Smart Consumables segment is engaged in developing and selling scientific materials, such as nucleic acid purification.
